Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price upped by Piper Sandler from $34.00 to $50.00 in a report ...

Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...

Scotiabank raised the firm’s price target on Guardant Health (GH) to $52 from $47 and keeps an Outperform rating on the shares. Guardant Health ...

Fear and anxiety may be the key reasons why patients are choosing not to undergo screenings for colorectal cancer. A study conducted by the Harris Poll and Palo Alto, Calif-based Guardant Health asked ...

Globant S.A. , a digitally native technology services company (the "Company"), announced today that it filed its annual report on Form 20-F for the year ended December 31, 2024 (the "2024 Annual ...

SOVRA is thrilled to announce its inclusion in the 2025 GovTech 100, an annual list spotlighting the companies redefining how governments leverage technology to serve their communities. This ...

Is Guardant Health (GH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.